Working… Menu

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00397800
Recruitment Status : Unknown
Verified August 2012 by Technische Universität München.
Recruitment status was:  Active, not recruiting
First Posted : November 10, 2006
Last Update Posted : August 28, 2012
Information provided by (Responsible Party):
Technische Universität München

Brief Summary:

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Giving rituximab and chemotherapy together with yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of yttrium Y 90 ibritumomab tiuxetan when given together with rituximab, fludarabine, and cyclophosphamide and to see how well they work in treating patients with relapsed B-cell non-Hodgkin's lymphoma.

Condition or disease Intervention/treatment Phase
Lymphoma Biological: rituximab Drug: cyclophosphamide Drug: fludarabine phosphate Radiation: yttrium Y 90 ibritumomab tiuxetan Phase 1 Phase 2

Detailed Description:



  • Determine the dose-limiting toxicity and maximum tolerated dose of rituximab and yttrium Y 90 (^90Y) ibritumomab tiuxetan when administered with rituximab as radioimmunotherapy after rituximab, fludarabine, and cyclophosphamide in patients with relapsed indolent, mantle cell, or transformed CD20-positive B-cell non-Hodgkin's lymphoma.


  • Determine the overall survival in patients treated with this regimen.
  • Determine time to progression and event-free survival in patients treated with this regimen.
  • Determine partial and complete response rates in patients treated with this regimen.
  • Determine time to maximal response in patients treated with this regimen.
  • Determine response duration in patients treated with this regimen.
  • Determine the feasibility of additional antineoplastic treatment following disease relapse after treatment with rituximab and ^90Y ibritumomab tiuxetan in these patients.

OUTLINE: This is a prospective, nonrandomized, multicenter, phase I dose-escalation study of yttrium Y 90 (^90Y) ibritumomab tiuxetan followed by a phase II open-label study.

  • Phase I:

    • Chemoimmunotherapy: Patients receive rituximab IV on day 1 and fludarabine IV over 30 minutes and cyclophosphamide IV over 60 minutes on days 1-3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression. Four weeks after the first day of the last chemoimmunotherapy course, patients receive 1 dose of rituximab IV alone. Patients with disease progression are removed from the study. Patients with stable disease proceed to radioimmunotherapy 8-12 weeks after the first day of the last chemoimmunotherapy course.
    • Radioimmunotherapy: Patients receive rituximab IV and an imaging dose of indium In III ibritumomab tiuxetan IV over 10 minutes on day 1. Patients then undergo imaging. If dosimetry is acceptable, patients receive rituximab IV and ^90Y ibritumomab tiuxetan IV over 10 minutes on day 8.

Cohorts of 3-6 patients receive escalating doses of ^90Y ibritumomab tiuxetan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

  • Phase II: Patients receive chemoimmunotherapy and radioimmunotherapy as in phase I, at the MTD determined in phase I.

Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for up to 2 years.

PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Sequential Treatment With a Combination of Rituximab, Fludarabine and Cyclophosphamide Followed by Zevalin (Rituximab and Y-Ibritumomab Tiuxetan) - A Phase I/II Study for Treatment of Patients With Relapsed Indolent and Transformed CD20-Positive B-Cell Non-Hodgkin's-Lymphoma Ineligible for High-Dose Chemo(Radio)Therapy Supported by Autologous Peripheral Blood Stem-Cells
Study Start Date : June 2005
Actual Primary Completion Date : May 2008
Estimated Study Completion Date : May 2013

Primary Outcome Measures :
  1. Dose-limiting toxicity

Secondary Outcome Measures :
  1. Response
  2. Survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed CD20-positive B-cell non-Hodgkin's lymphoma (NHL), including any of the following subtypes:

    • Indolent NHL, including any of the following:

      • Follicular
      • Lymphoplasmacytoid
      • Marginal zone
    • Mantle cell NHL
    • Transformed B-cell NHL
  • In at least first relapse with an indication for systemic antineoplastic treatment, as defined by the following:

    • Local or constitutional (B-) symptoms
    • Hypersplenism due to splenic involvement
    • Bulky disease (> 7.5 cm in diameter)
    • Impending medical problems derived from rapid disease progression within the past 6 months, as defined by an observed or anticipated > 50% increase in the sum of the areas calculated from multiplying the greatest perpendicular diameters of each lesion
  • Measurable lesions of lymphoma infiltration
  • Medically ineligible for high-dose treatment followed by autologous stem cell support
  • Adequate bone marrow cellularity (> 15% of marrow area covered by hematopoiesis)
  • No CNS, leptomeningeal, spinal cord, or testes lymphoma involvement
  • No lymphoma lesion mandating emergency radiotherapy
  • No clinical, cytological, cytogenetic, or histopathologic indication of myelodysplastic syndrome
  • If there is bone marrow infiltration detected prior to chemoimmunotherapy, patient must undergo a repeat bone marrow biopsy prior to planned treatment with radioimmunotherapy to verify the level of bone marrow infiltration is < 25%


  • ECOG performance status 0-2
  • Life expectancy ≥ 3 months
  • Absolute neutrophil count > 1,500/mm³
  • Platelet count > 150,000/mm³
  • Hemoglobin > 9 g/dL
  • Creatinine < 1.5 times upper limit of normal (ULN)
  • Bilirubin < 2 times ULN
  • ALT and AST < 2 times ULN
  • Albumin > 2.5 g/dL
  • INR < 1.5
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for ≥ 12 months after completion of study treatment
  • No concurrent severe and/or uncontrolled medical disease that would preclude study compliance, including any of the following:

    • Uncontrolled diabetes
    • Congestive heart failure
    • Chronic renal disease
    • Active uncontrolled infection
  • No bleeding risks or disorders, including any of the following:

    • CNS abnormalities suggesting an increased susceptibility for hemorrhage, including recent history of stroke as demonstrated by cranial contrast-enhanced CT scan
    • Severe arrhythmia or uncontrolled hypertension
    • Myocardial infarction within the past 6 months
    • Diabetic retinopathy with history of symptomatic hemorrhage
    • Known and potentially active gastrointestinal bleeding foci
    • Concurrent anticoagulant medication that must be continued even with platelet count < 20,000/mm³ (e.g., following mitral valve replacement, anti-phospholipid syndrome, or recurrent venous thromboembolism)
    • Other congenital or acquired hemorrhagic diatheses
  • No ongoing autoimmune hemolytic anemia
  • No known presence of anti-murine antibody reactivity
  • No known hypersensitivity to murine or chimeric antibodies or proteins
  • No known HIV infection
  • No psychiatric illness that would preclude study requirements
  • No other malignant disorder within the past 10 years except basal cell carcinoma of the skin or carcinoma in situ of the cervix


  • See Disease Characteristics
  • Recovered from prior therapy
  • No more than 4 prior systemic anti-lymphoma regimens (including single-agent rituximab)
  • At least 2 months since prior systemic anti-lymphoma treatment (including single-agent rituximab)
  • No prior radioimmunotherapy
  • No prior autologous or allogeneic hematopoietic stem cell transplantation
  • No prior treatment with purine analogues that has not resulted in remission for > 1 year
  • No prior anti-CD20 radioimmunoconjugate therapy
  • More than 5 years since prior radiotherapy to extensive fields covering lymph node regions on both sides of the diaphragm or > 50% of the spinal column
  • More than 4 weeks since prior surgery
  • No concurrent oral anticoagulant therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00397800

Layout table for location information
Medizinische Klinik, Klinikum Augsburg
Augsburg, Germany, D-86156
Medizinische Klinik III - Universitaetsklinikum Erlangen
Erlangen, Germany, D-91054
Universitaetsklinikum Goettingen
Goettingen, Germany, D-37075
Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
Luebeck, Germany, D-23538
Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg
Magdeburg, Germany, D-39120
Universitatsklinik Mainz
Mainz, Germany, D-55101
LMU-Klinikum Grosshadern
Munich, Germany, D-81366
Klinikum Rechts Der Isar - Technische Universitaet Muenchen
Munich, Germany, D-81675
Klinikum der Universitaet Regensburg
Regensburg, Germany, D-93042
Universitaetsklinikum Tuebingen
Tuebingen, Germany, D-72076
Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm
Ulm, Germany, D-89081
Medizinische Klinik und Poliklinik II - Universitaetsklinikum Wuerzburg
Wuerzburg, Germany, D-97080
Sponsors and Collaborators
Technische Universität München
Layout table for investigator information
Study Chair: Christian Peschel, MD Technische Universität München
Layout table for additonal information
Responsible Party: Technische Universität München Identifier: NCT00397800    
Other Study ID Numbers: CDR0000515982
First Posted: November 10, 2006    Key Record Dates
Last Update Posted: August 28, 2012
Last Verified: August 2012
Keywords provided by Technische Universität München:
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
Waldenstrom macroglobulinemia
recurrent mantle cell lymphoma
recurrent marginal zone lymphoma
extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
nodal marginal zone B-cell lymphoma
splenic marginal zone lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Fludarabine phosphate
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Immunological
Antimetabolites, Antineoplastic